UiPath Hosts Second Annual #UiPathForward EMEA Conference in London
UiPath, the leading Enterprise Robotic Process Automation (RPA) software company, will host its second #UiPathForward EMEA event, along with headline sponsors Google Cloud Platform and Microsoft at the Royal Lancaster Hotel in London on the 30th October.
More than a thousand customers and partners will hear how RPA is accelerating digital transformation in all aspects of business from thought leaders such as UiPath CEO Daniel Dines, UiPath Chief Product Officer Param Kahlon and McKinsey Global Institute Director Jacques Bughin.
The event features the following highlights:
Ed Vaizey MP, former UK government minister for culture and the digital economy, will give a keynote address on digital transformation in business and government.
Sarah Burnett, executive vice president and distinguished analyst of Everest Group, will launch a new Smart RPA playbook during her presentation.
Jacqueline de Rojas, CBE and president of techUK, will lead an expert panel on digital inclusion and diversity, and how organisations can build a multigenerational community of automation professionals.
Other speakers at #UiPathForward EMEA include:
- Neil Davies, automation manager, Admiral Insurance, discussing 10 things Admiral has learned about robots,
- Brendan MacDonald, director of customer compliance operations, Ladbrokes Coral, discussing how RPA can deliver compliance,
- Dave Wright, partner/consulting, Deloitte, on scaling robotic and cognitive automation across the enterprise,
- Ashwin Yardi, chief industrialization and automation officer, and Carole Murphy, head of business transformation services, Capgemini, on building a bridge between IT and the business.
“The era of RPA has arrived, and it is accelerating the pace of digital transformation across the region,” said Kulpreet Singh, managing director, EMEA, UiPath. “We’re looking forward to #UiPathForward EMEA and sharing insights into how RPA is creating a digital workforce that helps businesses in the region scale quickly and achieve rapid results.”
At the event, guests will learn more about UiPath Go! – the collaborative platform designed to accelerate the implementation of RPA through the sharing of knowledge and solutions by teams, partners, customers and freelancers.
The winners of the Power Up Automation Hackathon will also be announced, in which competitors were invited to build open source, reusable components with UiPath Studio.
Partner sponsorships for UiPath Forward are sold out, with sponsors including Google, Microsoft, Capgemini, Deloitte, ABBYY, Accenture, Bizagi, Celonis, Cognizant, Enate, Genpact, IBM, K2, Oracle, Protiviti, PwC, Roboyo, Symphony Ventures and Voyager Solutions.
To learn more on Twitter please follow the hashtag #UiPathForward and to attend please visit the registration page.
Built for both business and IT, UiPath is the leading platform for enterprise Robotic Process Automation (RPA). More than 1,800 business customers and government agencies use UiPath's Enterprise RPA platform to rapidly deploy software robots that perfectly emulate and execute repetitive processes, boosting business productivity, ensuring compliance and enhancing customer experience across back-office and front-office operations.
With a thriving RPA developer community of more than 250,000 worldwide, UiPath is on a mission to democratize RPA and support a digital business revolution. Based in New York City, UiPath’s presence extends to 14 countries throughout North America, Europe and Asia. The company is backed by over $400M in funding from Accel, CapitalG, KPCB, Credo Ventures, Earlybird’s Digital East Fund, Sequoia Capital and Seedcamp.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EET | Tiedote
Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi
Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EET | Tiedote
Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W
bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EET | Tiedote
A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EET | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in
AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EET | Tiedote
Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin
Historic Partnership between the Weizmann Institute of Science and Institut Curie25.3.2019 19:54:00 EET | Tiedote
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics. Collaborative research programs This partnership will extend to many disciplines, including physics, chemistry, cellular biology, epigenetics, genetics, immunology and single cell approaches, imagery and data collection. The complementarity of the research between the various groups at Institut Curie and at the Weizmann Institute has been recognized in particular at the occasion of joint scientific workshops held regularly alternatively in Paris and Rehovot.
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme